Medpace's Third Quarter 2026: A Backlog Engine Keeps Metrics Purring for MEDP

Medpace Holdings, Inc. (Nasdaq: MEDP) reported Q3 2026 results, with EPS and revenue metrics that invite a closer look at the drumbeat behind the CRO's earnings rhythm.

Overview: Revenue Up, Backlog Steady, Cash to Burn (or not)

The Medpace report for the quarter ended September 30, 2026 shows a company maneuvering a robust top line into a larger backlog and healthy profitability. Revenue reached $716.0 million in the third quarter, up 8.5% from $659.9 million in the prior-year period. On a constant currency basis, the pace is nearly identical at an 8.6% improvement, suggesting the growth is not simply a currency story.

The backlog sits at $3,167.2 million as of September 30, 2026, representing a 5.6% year-over-year expansion, while net new business awards totaled $873.4 million in Q3, a 10.6% increase versus the comparable prior year. If you’re keeping score, backlog conversion remains a useful indicator of revenue visibility as the company converts demand into realized results.

GAAP net income for the quarter was $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86 per diluted share in the prior-year period. Net income margin rose to 19.2% from 16.8%. EBITDA stood at $172.1 million, or 24.0% of revenue, up from $148.4 million (22.5% margin) in the prior-year period.

Profitability and per-share frame

The quarterly EPS figure—$4.84 per diluted share—sits alongside the revenue milestone to present a consistent profitability narrative. The year-over-year improvement in net income and margin aligns with the EBITDA expansion, painting a picture of efficient operation alongside top-line growth.

For the nine months ended September 30, 2026, Medpace reported revenue of $2,129.9 million, up 16.9% on a reported basis and 16.7% on a constant currency basis. Year-to-date GAAP net income totaled $382.7 million, or $13.37 per diluted share, and EBITDA reached $474.9 million, equating to 22.3% of revenue. Those tallies continue to reflect a business delivering scale with margin resilience.

On a margin basis, the company is performing within a range that supports ongoing operating leverage. EBITDA margin for the quarter was 24.0%, and the year-to-date EBITDA margin sits over 22% of revenue, a tone that suggests healthy operating leverage even as the base grows.

Cash, liquidity, and capital allocation

Medpace ended the quarter with cash and cash equivalents of $705.3 million. Operating cash flow for the quarter was $216.6 million, underscoring the business's ability to fund operations and potential investments from internally generated cash.

There were no share repurchases in the third quarter of 2026, and as of September 30, 2026, the company had $527.0 million remaining under its authorized share repurchase program. In other words, the capital allocation posture remains on the table, albeit not being exercised in the latest quarter.

What this signals for Medpace and its peers

The Q3 results reinforce Medpace's standing as a contract research organization with tangible demand tailwinds reflected in backlog growth and a solid net-new award trajectory. A few takeaways stand out for investors and industry observers alike:

Backlog as a barometer: Backlog of $3.17 billion provides revenue visibility into the next several quarters. The 5.6% year-over-year increase suggests the demand environment remains healthy, even as the company faces rising base costs and potential FX headwinds implied by the constant currency framing.
Growth vs. profitability balance: The expansion in GAAP net income and the EBITDA margin uplift point to a favorable mix and operational efficiency. If the company sustains this balance, the path to mid-teens revenue growth with mid-20s EBITDA margins looks defensible, albeit cyclical and tied to sponsor funding and trial activity cycles.
Cash generation and capital discipline: A robust cash balance and meaningful operating cash flow give Medpace optionality—whether to pursue strategic investments, de-lever, or return capital. The absence of quarterly share repurchases in Q3 might reflect a cautious posture or a strategic pause as the company weighs opportunities in a changing market.
EPS framing and investor expectations: The reported EPS of $4.84 for the quarter and $13.37 for the nine months align with a trajectory of value creation, but the release does not provide an EPS consensus or any stated earnings surprise figure. That lack of guidance or consensus data leaves room for interpretation about where expectations sit and how management might guide the market going forward.
Revenue forecast visibility: The press release emphasizes quarterly and year-to-date results but does not include a formal revenue forecast for the remainder of the year. In a sector where clinical trial momentum can swing on regulatory timelines and sponsor pipelines, the absence of near-term guidance may keep analysts focused on backlog and realization rates as a primary signal.

From a sector lens, Medpace's results highlight that CROs with a steady backlog and disciplined cost structure can translate top-line momentum into meaningful margin expansion. Peer groups—ranging from midsize specialists to larger, diversified CROs—might interpret this as confirmation that disciplined pricing, project execution, and a portfolio of long-running programs can yield consistent profitability even as biopharma sponsors navigate capital allocation and trial pacing differently.

Notes on the disclosure

The release foregrounds GAAP metrics and non-GAAP EBITDA reconciliation, a common framing in earnings communications. It does not appear to publish an EPS consensus or an explicit earnings surprise in this filing, and there is no stated revenue forecast for the full year in the excerpt provided. The data reflect a snapshot from the press materials accompanying the SEC filing EX-99.1, dated October 21, 2026, with the Cincinnati, Ohio timestamp anchoring the release.

Bottom line

Medpace's Q3 2026 results underscore a company generating solid top-line growth and converting demand into earnings momentum, all while maintaining robust cash generation and a sizable unused buyback capacity. For MEDP, the next act will hinge on how backlog stacks up against project completions, whether management provides additional color on revenue guidance, and how sector peers respond to a backdrop where trial activity can swing with sponsor pipelines. If you're tracking EPS, revenue forecast, and earnings surprise in this space, Medpace offers a clean case study in how backlog depth and margin discipline translate into a credible quarterly narrative—even when the forecast remains a touch cloudy.